243 related articles for article (PubMed ID: 37450122)
1. Role of Circulating Tumor DNA in Colorectal Cancer.
Li H; Lu S; Zhou Z; Zhu X; Shao Y
Methods Mol Biol; 2023; 2695():227-236. PubMed ID: 37450122
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.
Zhou H; Zhu L; Song J; Wang G; Li P; Li W; Luo P; Sun X; Wu J; Liu Y; Zhu S; Zhang Y
Mol Cancer; 2022 Mar; 21(1):86. PubMed ID: 35337361
[TBL] [Abstract][Full Text] [Related]
3. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
4. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
5. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
8. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of circulating tumor DNA for colorectal cancer.
Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
[TBL] [Abstract][Full Text] [Related]
11. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
Zhang X; Hou H; Jiang M; Zhang X
Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
[TBL] [Abstract][Full Text] [Related]
12. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
13. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of circulating tumour DNA in colorectal cancer.
Loft M; To YH; Gibbs P; Tie J
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):837-852. PubMed ID: 37499673
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
[TBL] [Abstract][Full Text] [Related]
17. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
18. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
20. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.
Hedtke M; Pessoa Rejas R; Froelich MF; Ast V; Duda A; Mirbach L; Costina V; Martens UM; Hofheinz RD; Neumaier M; Haselmann V
Mol Oncol; 2022 May; 16(10):2042-2056. PubMed ID: 34873826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
